{
    "Trade/Device Name(s)": [
        "Liberty Glucose Control MID"
    ],
    "Submitter Information": "Liberty Healthcare Group, Inc.",
    "510(k) Number": "K052980",
    "Predicate Device Reference 510(k) Number(s)": [
        "K983504"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJX"
    ],
    "Summary Letter Date": "November 30, 2005",
    "Summary Letter Received Date": "October 24, 2005",
    "Submission Date": "October 20, 2005",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [],
    "Specimen Container(s)": [
        "Plastic bottle with dropper tip"
    ],
    "Instrument(s)/Platform(s)": [
        "Abbott Medisense Optium",
        "Precision",
        "Precision 3",
        "Precision Xtra Blood Glucose Monitors"
    ],
    "Method(s)/Technology(ies)": [],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control",
        "Quality control material"
    ],
    "Document Summary": "FDA 510(k) summary for Liberty Glucose Control MID, a single analyte glucose control solution for assessing performance of Medisense blood glucose monitors",
    "Indications for Use Summary": "For in vitro diagnostic use by healthcare professionals and home users with diabetes mellitus to assess the performance of Medisense Optium, Precision, Precision 3, and Precision Xtra Blood Glucose Monitors",
    "fda_folder": "Clinical Chemistry"
}